Here are the 424B prospectus supplements from VCI Global Limited (VCIG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VCIG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCIG filings page.
VCI Global Ltd (VCIG) filed a prospectus supplement that amends its March 6, 2026 prospectus supplement to significantly narrow the securities covered. The earlier document related to an institutional offering of ordinary shares, pre-funded warrants, and two series of common warrants under a securities purchase agreement with a single investor.
The new supplement limits coverage to 81,500 Ordinary Shares, including shares issued upon exercise of pre-funded warrants. All of these ordinary shares have already been sold and issued as of the date of this supplement, so the document mainly aligns the registration disclosure with the actual issuance.
The share counts in the supplement reflect a 1-for-60 reverse stock split effective February 27, 2026 and a 1-for-15 reverse stock split effective August 24, 2026. VCIG’s ordinary shares trade on Nasdaq under the symbol VCIG; on August 21, 2026, the last reported sale price was $0.2129 per share. The company states it qualifies as an “emerging growth company” and a foreign private issuer, which allows reduced U.S. reporting requirements.
VCI Global Ltd (VCIG) filed a prospectus supplement reducing the securities covered under its January 2026 prospectus supplement to 63,986 Ordinary Shares. These consist of 9,526 Ordinary Shares issued (including upon exercise of Pre-Funded Warrants) and 54,460 Ordinary Shares issued upon exercise of Common A Warrants.
All Ordinary Shares covered have been sold and issued. The share numbers reflect a 1-for-60 reverse stock split on February 27, 2026 and a 1-for-15 reverse stock split on August 24, 2026. VCIG’s Ordinary Shares trade on Nasdaq under “VCIG,” with a last reported sale price of $0.2129 on August 21, 2026. The company highlights significant risk factors and its status as an emerging growth company and foreign private issuer.
VCI Global Ltd (VCIG) filed a prospectus supplement adjusting its previously registered equity line transaction with Alumni Capital LP. The supplement now reflects a total of up to 19,203 ordinary shares, consisting of Purchase Shares issued under a Purchase Agreement and Warrant Shares issuable under a three-year Commitment Warrant.
The amendment decreases the maximum Purchase Shares to 2,485 ordinary shares and the maximum Warrant Shares to 16,718 ordinary shares, with share counts adjusted for a 1-for-60 reverse stock split on February 27, 2026 and a 1-for-15 reverse stock split on August 24, 2026. VCI Global states it has already issued and sold all Offered Shares and received $26,980,364.28 in proceeds under the Purchase Agreement. Alumni Capital is treated as an underwriter under the Securities Act. VCIG’s ordinary shares trade on the Nasdaq Capital Market under the symbol VCIG, with a last reported price of $0.2129 per share on August 21, 2026.
VCI Global Ltd (VCIG) filed a prospectus supplement amending an earlier convertible note prospectus supplement to change the number of ordinary shares issuable to Alumni Capital LP under an August 13, 2025 Securities Purchase Agreement. The registered amount is now 19,990 ordinary shares, reduced from 55,556 ordinary shares, issuable upon conversion of convertible notes and exercise of warrants issued under that agreement.
The share figures reflect a 1-for-60 reverse stock split effective February 27, 2026 and a 1-for-15 reverse stock split effective August 24, 2026. The company states that all shares covered by this supplement have been sold and issued. VCIG’s ordinary shares trade on Nasdaq under the symbol VCIG, and the last reported sale price on August 21, 2026 was $0.2129 per share. VCI Global is classified as an emerging growth company and uses certain reduced reporting requirements.
VCI Global Limited is registering a mixed package of securities comprising 4,584,352 Ordinary Shares, Pre-Funded Warrants to purchase up to 4,584,352 Ordinary Shares, Common A Warrants to purchase up to 9,168,705 Ordinary Shares, and Common B Warrants to purchase up to 9,168,705 Ordinary Shares for sale directly to a single institutional investor pursuant to a Securities Purchase Agreement.
The Investor agreed to buy the Offered Securities in three tranches of $5,000,000 each; the Initial Closing occurred on March 6, 2026 and included 225,241 Ordinary Shares, Pre-Funded Warrants for 997,253 Ordinary Shares, Initial Common A Warrants for 1,222,494 Ordinary Shares and Initial Common B Warrants for 1,222,494 Ordinary Shares. Exercise prices and terms are disclosed, including an Initial Common A and B exercise price of $5.62 and Pre-Funded Warrant nominal exercise price of $0.0001. The offering contemplates subsequent closings subject to trading-price, volume and other conditions and lists Nasdaq symbol VCIG.
VCI Global Limited is conducting a primary offering of 32,150,205 ordinary shares, together with pre-funded warrants for up to 32,150,205 shares and Common A and B warrants for up to 64,300,410 shares each, in three tranches of $5,000,000 each. The initial closing includes 3,179,716 shares, pre-funded warrants for 5,393,672 shares, and Common A and B warrants for 8,573,388 shares each, sold at combined prices of $0.5832 per share unit and $0.5831 per pre-funded warrant unit. Common A warrants have a five-year term and Common B warrants a 180-day term, both initially exercisable at $0.8020 per share with anti-dilution adjustments and, for Common A, cashless exercise and forced exercise features. If all offered shares and all warrants are fully exercised, ordinary shares outstanding would rise to 221,839,852 from 32,118,338 as of January 20, 2026. Each tranche depends on trading price, volume and listing conditions, and net proceeds of about $4.625M per tranche are earmarked for working capital and general corporate purposes.